Vanguard Personalized Indexing Management LLC Acquires 22,993 Shares of Geron Corporation $GERN

Vanguard Personalized Indexing Management LLC raised its stake in Geron Corporation (NASDAQ:GERN) by 204.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,238 shares of the biopharmaceutical company’s stock after acquiring an additional 22,993 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Geron were worth $48,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Geron by 2.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock valued at $627,000 after purchasing an additional 8,123 shares during the last quarter. Frisch Financial Group Inc. grew its position in Geron by 84.3% during the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 8,700 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of Geron by 33.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 78,289 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 19,426 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Geron by 13.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 170,441 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 20,133 shares during the period. Finally, Zuckerman Investment Group LLC raised its stake in Geron by 28.8% during the first quarter. Zuckerman Investment Group LLC now owns 103,000 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 23,000 shares in the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GERN has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Geron in a research note on Wednesday, October 8th. The Goldman Sachs Group initiated coverage on shares of Geron in a report on Thursday, July 10th. They issued a “sell” rating and a $1.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Geron currently has an average rating of “Hold” and a consensus target price of $3.79.

Geron Stock Up 3.2%

GERN stock opened at $1.28 on Tuesday. The company’s 50 day moving average price is $1.33 and its 200 day moving average price is $1.36. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 7.87. Geron Corporation has a fifty-two week low of $1.09 and a fifty-two week high of $4.50. The firm has a market capitalization of $816.67 million, a price-to-earnings ratio of -9.85 and a beta of 0.57.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $49.04 million for the quarter, compared to analyst estimates of $47.30 million. Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%. The firm’s revenue was up 5455.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.10) earnings per share. On average, equities research analysts anticipate that Geron Corporation will post -0.25 EPS for the current fiscal year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.